Announcing
an important advance
in the treatment
of a neoplastic disease

‘ALKERAN’
brand
MELPHALAN

for the treatment of
MULTIPLE MYELOMA

—the L-phenylalanine derivative of nitrogen mustard, also known as Compound CB 3025 and L-Sarcolysin, is useful in the treatment of multiple myeloma. Although there is no cure for multiple myeloma, ‘Alkeran’ brand Melphalan is considered by leading authorities to be a real advance which provides substantial benefit to one-third to one-half of the patients treated.

Contraindications and Precautions: ‘Alkeran’ brand Melphalan should not be given if other similar chemotherapeutic agents or radiation has been administered in the recent past, or if the neutrophil and/or platelet counts are depressed. It should not be administered concurrently with radiation. If the leukocyte count falls below 3,000 cells/cu.mm., or the platelet count goes below 100,000 cells/cu.mm., the drug should be discontinued until the blood picture has had a chance to recover. Whenever possible, use of the drug should be avoided during the first trimester of pregnancy.

Preparation: 2 mg., Scored Tablets, Bottles of 50.

Complete information available from your ‘B.W. & Co.’ Representative or from Professional Services Dept. PML.

BURROUGHS WELLCOME & CO. (U.S.A.) INC., Tuckahoe, N.Y.
Corscaden: GYNECOLOGIC CANCER, 3rd edition

The importance of early diagnosis in the care and cure of female cancers is gaining recognition and acceptance by gynecologists, general practitioners, and the public. More than six million American women will have the Papanicolaou smear test this year. Yet, more than 40 million should have this test but do not—many of these women have never even heard of it.

Dr. James A. Corscaden shows great concern about this problem. Dr. Corscaden was one of the early advocates of early diagnosis and early treatment for cancers of the female productive organs. In his new third edition of Gynecologic Cancer, he explains in detail, tested methods of diagnosis and treatment, giving careful attention to new methods developed within the past decade. Evident throughout this book are Dr. Corscaden's broad knowledge of research in his subject and his long experience as both a surgeon and gynecologist.

He is perhaps best known for establishing the Follow Up System in the Surgical Department of the Presbyterian Hospital in New York City and for taking part in the development of the Unit History System, both of which have become standard in most hospitals. Dr. Corscaden established the Department of Radiotherapy at the Presbyterian Hospital and organized and took charge of the Tumor Clinic at the Sloane Hospital for Women.

He has collected many excellent x-rays, diagrams, and photomicrographs which he reproduces in Gynecologic Cancer. Dr. Edmund R. Novak concluded his highly favorable review in Obstetrical and Gynecological Survey of the second edition of this book with the following: "No finer summary or reference text can be found, but above all, it is an eminently well-balanced book with consideration of all means of therapy, but without any undue prejudice or bias. As such it is highly recommended to all doctors who see female patients."

CONTENTS: Introduction • Diagnosis • Cancer of the vulva • Cancer of the vagina • Cancer of the cervix • Cancer of the endometrium. Cancer of the myometrium • Neoplastic diseases of the chorion • Cancer of the fallopian tube • Cancer of the ovary • The menopause • Management of the cancer patient • The nature of cancer • Index.

By JAMES A. CORSCADEN, Ph.B., M.D., Professor Emeritus of Clinical Gynecology
College of Physicians and Surgeons, Columbia University
Attending Gynecologist, Sloane Hospital for Women, New York

1962 • 585 pp., 117 figs. • $12.00

THE WILLIAMS & WILKINS COMPANY
428 E. PRESTON STREET/BALTIMORE, MARYLAND, U.S.A. 21202
INSTRUCTIONS FOR AUTHORS

 Manuscripts for Cancer Research must represent new and original contributions not previously published and, if accepted, not to be published elsewhere. They must be typed, double-spaced (including references, footnotes, and tables), with ample margins, on bond paper. The original and one clear copy of the entire manuscript, including figures and charts, must be submitted. All pages should be numbered consecutively. Every paper must begin with a concise summary of the essential results of the investigation.

 Supplements on Cancer Chemotherapy Screening Data. Authors who wish to submit data for publication in these supplements, which appear at least six times a year, are urged to consult the Instructions for the preparation of such material, found on the inside back cover of most of these supplements.

 Critical reviews on subjects dealing with cancer and allied fields will be considered for publication. Such reviews should attempt to correlate the various approaches to a problem so as to indicate the trends and emphasize the aspects that require further clarification. Critical analyses of the pertinent issues and expressions of opinions are encouraged.

 The title of the paper should be as short as is compatible with a clear indication of the subject matter. The title (with subtitle, if any) must not exceed 150 characters and spaces. Chemical formulas should not be included in the title. The title of the paper, author (or authors), location, and any acknowledgments should appear on separate pages.

 Footnotes within the text should be numbered consecutively and should appear on a separate sheet.

 Tables should be typed, double-spaced throughout, on separate sheets and should be numbered. Each must have a brief, descriptive title. Tables should be arranged for vertical position on the page. Every column must be supplied with an appropriate heading and units of measure must be clearly indicated. The same data may be presented in either chart or tabular form, but not in both. Tables should be intelligible without reference to the text.

 Illustrations: The preparation of photographs, charts, and graphs is particularly important, and authors are requested to follow carefully the directions given below.

 Half-tone illustrations (photomicrographs and photographs) are designated figures and are printed as plates at the end of each article. Figures in moderate numbers will be accepted if they are of good technical quality and essential for the clarity of the presentation. Figures should be trimmed to show only the essential features; all parts of each figure must be in sharp focus. Only clear, glossy photographs should be submitted. Mount all photographs on white cardboard (8½×11 inches in size), with the edges abutting tightly. The engraver will then draw a thin line between adjoining figures. Place as many together as will make a plate not to exceed 7½×10½ inches. Figures should be numbered consecutively. Photographs of plates should accompany the second copy of the manuscript. Legends for plate figures should be typed separately, in consecutive order, on standard-sized paper with the heading “Legends for Figures.”

 Line-cut illustrations (graphs and charts) are designated charts and are printed in the text. These should be numbered in consecutive order. Charts should be planned so as to eliminate waste space; they must be ruled off close to the area of the curves, and descriptive matter must not extend beyond the curves. Charts must be so prepared that no letter or figure will be less than 2 mm. high after reduction. The majority of charts can be reduced to a one-column (3½-inch) width, but larger ones are permissible when many data are included in one chart. Original line drawings on high-quality white drawing paper or board, blue tracing cloth, or coordinate paper printed in blue should be used. Only India ink should be used for drawing or lettering. Photographs of the charts should accompany the second copy of the manuscript. Legends for each chart should be typed separately in consecutive order on standard-sized paper with the heading “Legends for Charts.” The over-all size of mounted charts and plates must not exceed 8½×11 inches. When original drawings exceed this size, photographed reductions must be sent.

 References must be typed double-spaced and should include, in order: author, title, journal abbreviation (Chemical Abstracts form), volume number in Arabic numerals, inclusive pages, and year. Book references should give: author, title, pages, edition number, city, publisher, and year. All references should be checked with the original publications and must be arranged in alphabetical order. Each number in the references is to refer to only one paper. Unpublished data and personal communications may not be included in “References” but must be listed as footnotes. For an example of the correct style, refer to any current issue of Cancer Research.

 Changes in proof: Any but minor changes from the manuscript which are made in proof will be billed to the author.

 Reprints may be ordered before publication, according to a schedule of prices accompanying the galley proof of the article.

 Manuscripts and correspondence related to contributions should be addressed to: Dr. Harold P. Rusch, Editor, Cancer Research, McArdle Memorial Laboratory, Madison, Wisconsin 53706.

 INFORMATION FOR SUBSCRIBERS

 All subscriptions and business inquiries should be addressed to the publishers, The Williams & Wilkins Co., 428 E. Preston St., Baltimore, Md., U.S.A., 21202.
NEW PURITY STANDARDS
two important biochemicals for clinical determination

BILIRUBIN
Serum Bilirubin determinations in infants suffering from erythroblastosis fetalis have proved an important criteria for the use of exchange transfusions. The accuracy of this measurement has always been open to question because of uncertainty about the purity of bilirubin (1).

Our specifications for Bilirubin are:
(1) Millimolar extinction coefficient of 60.1 ±0.2 in Chloform at 453 mu.
(2) Complete and rapid solubility at room temperature (for concentration of 6mg/100ml.) in chloform or 0.2% solution of Na2CO3.

The problem of finding an accurate method for bilirubin determination has occupied clinical chemists for 50 years. For determinations of new-born plasma, the most useful procedure is the Lathe and Rutheven (2) modification of the Malloy-Evelyn method (3). Stoner and Weisberg have recently reported an excellent micromethod for bilirubin (4).

For accurate determinations of low values of bilirubin, methods of choice are those of Bruckner (5) and Jendrassik and Grof (6). The methods of Meites and Hogg (7), and Powell (8) have the advantage of rapidity and involve few manipulative steps for the laboratory that does not have access to specialized equipment.

PRICE SCHEDULE:
5 gram bottle . . . . . . . gm. $14.90
1 gram bottle . . . . . . . gm. 17.90
500 mg. bottle . . . . . . . btl. 10.90


PHONE COLLECT, 216-662-0212.
NUTRITIONAL BIOCHEMICALS CORP.
GUARANTEES SHIPMENT WITHIN 60 MINUTES OF YOUR CALL. ONE DAY DELIVERY ANYWHERE IN CONTINENTAL U.S.A.

CHOLESTEROL S.C.W.
Cholesterol S.C.W. (standard for clinical work) was developed in our laboratories by the intensive purification of Cholesterol U.S.P. to fill the need for a reliable, pure clinical standard.

Our specifications for Cholesterol S.C.W. are:
Molar absorptivity values, Lieberman-Buchard method: 1750 ±30. Sulphuric Acid iron method: 11,500 ±100. To the best of our knowledge, this is the first time that cholesterol of this purity has been available commercially.

When Cholesterol U.S.P. is used as a standard an error of approximately 6% in concentration is introduced, and can run as high as 14% in molar absorptivity. This depends upon the amount of such impurities as cholestanol chole-7-en-3-beta ol, and 7-dehydrocholesterol that are contained in the cholesterol.

PRICE SCHEDULE:
100 grams . . . . . . . . gm. $3.80
25 grams . . . . . . . . . gm. .90
5 grams . . . . . . . . . gm. .95


THE LITERATURE REFERENCES SHOULD NOT BE INTERPRETED AS EITHER AN ENDORSEMENT OR DISAPPROVAL OF THE BIOCHEMICAL BY THE CITED INVESTIGATOR.

NUTRITIONAL BIOCHEMICALS CORPORATION
21010 Miles Avenue • Cleveland, Ohio 44128
Send for free May 1964 catalog containing more than 3,000 items. Fill out coupon and mail today for your copy.

Name _____________________________
Organization _________________________
Address ______________________________
City ________________________ State ________ Zip No. __________________